close_btn.png
Healthcare Professionals|Patients/Caregivers rgt_arr.png
Close

You are about to leave NETrospectives and enter a website operated by an independent third party. Please click continue if you wish to be taken to this website.

Cancel
Continue
Explore

Evidence of an increasingly common problem

A 2.7-fold increase in incidence

According to Surveillance, Epidemiology, and End Results (SEER) data, the age-adjusted incidence of NETs rose from 1.9 to 5.25 cases per 100,000 people between 1973 and 2004.4 Diagnosed incidence of NETs is predicted to continue rising at a faster rate than other malignant neoplasms.7 This may be due to improved surveillance and diagnostic techniques.8

The SEER database is a comprehensive cancer statistics program operated by the National Cancer Institute. SEER is widely used to establish the epidemiologic landscape for various types of cancer throughout the world.

Incidence increased faster than other Neoplasms (SEER data, 1973-2004)

NETs are more prevalent than stomach and exocrine pancreatic cancers combined.4,9

Have you seen NETs in your practice?

SEER data also demonstrate that the prevalence of NETs is similar to that of other types of gastrointestinal cancers.4

Most NETs occur sporadically. However, some may be associated with genetic syndromes, notably multiple endocrine neoplasia type 1 (MEN-1), as well as MEN-2a and MEN-2b.2,3

Chart showing that Neuroendocrine Tumors (NETs) are more prevalent than stomach and pancreatic cancers combined.

Early detection may help reduce rates of metastatic disease

As with other solid tumors, 5-year survival rates for patients with NETs depend largely on the tumor histology and extent of disease. The table at right shows 5-year and median survival for both well-differentiated NETs and poorly differentiated neuroendocrine neoplasms, according to long-term SEER data (1973-2004).4

5-year survival rates for patients with Neuroendocrine Tumors (NETs)

About 50% of patients with reported disease stage have either regional or distant metastases at diagnosis.4

This reflects, in part, the long delay that can occur (up to 5 to 7 years for certain types of NETs)2 before patients are definitively diagnosed and optimally managed.

Extent of disease at diagnosis also varies according to location of the primary tumor, as shown at right.4

Neuroendocrine Tumor (NET) Disease extent of selected sites at diagnosis.

page 2
page 3